SHIBUYA CORPORATION
6340・Prime Market・Machinery
Business
Shibuya Kogyo is an industrial machinery manufacturer headquartered in Kanazawa, Ishikawa Prefecture, founded in 1949. The group consists of 18 subsidiaries and operates three businesses: (1) the Packaging Plant Business, which provides filling and packaging systems for beverages, food, and pharmaceuticals (net sales of ¥80,081 million); (2) the Mechatronics System Business, which handles semiconductor manufacturing equipment, artificial dialysis equipment, and cutting processing machines (net sales of ¥37,765 million); and (3) the Agricultural Equipment Business, which provides fruit sorting and grading systems for agricultural cooperatives (net sales of ¥11,170 million). Major customers include soft drink, alcoholic beverage, food, and pharmaceutical manufacturers, as well as OEM partners such as Nipro Corporation (16.9% of net sales). The company is listed on the Prime Market of the Tokyo Stock Exchange and the Premier Market of the Nagoya Stock Exchange.
Business Model
The company earns revenue by manufacturing custom-specification large-scale manufacturing systems to order for incorporation into customers' production lines, providing an integrated offering from delivery and installation through to maintenance services. In its core Packaging Plant Business, it holds an estimated 80-90% share of the domestic beverage aseptic filling system market, achieving high profitability (segment profit margin of 15.7% in FY2025 (ending June 2025)) backed by technological superiority. In the Mechatronics System Business, mass-production supply of Artificial Dialysis Equipment under OEM contracts serves as a stable revenue source.
Company Strengths
The company boasts an estimated domestic market share of 80–90% in aseptic filling systems for PET bottles. Its environmentally conscious technological advantages—such as compatibility with thin-walled bottles, high-speed filling for 100% recycled PET bottles, and electron-beam bottle sterilization—have earned strong support from many users. In FY2025 (ending June 2025), Packaging Plant Business sales reached ¥80,081 million (up 21.3% year on year), a record high.
Artificial Dialysis Equipment, the core product of the Mechatronics System Business, has an overseas sales ratio exceeding 80%, driven mainly by demand from China, India, and North America. In addition to the full-scale ramp-up of shipments to North America, the company has begun expanding the Wakamiya Plant for medical equipment, building a production system to meet growing demand amid the worldwide increase in dialysis patients.
In FY2025 (ending June 2025), consolidated net sales were ¥129,017 million (up 11.8% year on year), operating profit was ¥13,749 million (up 2.7% year on year), and profit attributable to owners of parent was ¥10,052 million (up 2.8% year on year), with both sales and profit reaching record highs. Net assets reached ¥107,930 million, maintaining a sound financial foundation.
ENVALITH's Perspective
Performance Trend
Over the past five fiscal years, revenue expanded from a trough of ¥96,223 million in FY2022 to ¥129,017 million in FY2025, but cumulative revenue of ¥96,521 million for the first three quarters of FY2026 (ending June 2026) (up 2.7% year on year) points to decelerating growth. Operating profit deteriorated sharply to ¥8,215 million (down 23.0% year on year). This was driven by a simultaneous profit decline in two businesses: the Mechatronics System Business (a downturn in wire bonders for LEDs and reduced production of medical equipment) and the Agricultural Equipment Business (low-profitability large-scale projects and increased depreciation burden following completion of the new head office plant). As an external factor, soaring labor costs, raw material costs, and energy costs pushed up the cost-of-sales ratio (cost of sales of ¥79,271 million, up 5.6% year on year), lowering the gross profit margin. The full-year forecast remains unchanged, and the key to a recovery in performance lies in the recording of revenue from the Agricultural Equipment Business and the effect of increased production of medical equipment in the fourth quarter.
Growth Strategy
Aiming for net sales of ¥150,000 million in FY2027 (ending June 2027) through three pillars: new products, new markets, and new businesses
Promoting order expansion for Beverage Aseptic Filling Systems for China and Southeast Asia, automated cell culture systems for Thailand, and injectable drug vial filling systems. Cumulative sales for pharmaceutical and cosmetics plants in the third quarter increased 34.0% year on year, achieving high growth, with progress being made in expansion into the pharmaceutical and regenerative medicine fields.
Began increased production of medical equipment (Artificial Dialysis Equipment), for which parts shortages have largely been resolved, building a system to compensate for the production cuts made through the second quarter. Bonders for optical communication modules continue to perform well. Order backlog is on a recovery trend, up 20.3% year on year to ¥14,218 million, and performance improvement is expected from the fourth quarter onward.
Orders received increased 78.5% year on year to ¥10,855 million, and order backlog increased 60.7% year on year to ¥11,932 million, with a substantial buildup continuing amid strong inquiries. However, cumulative results through the third quarter recorded an operating loss of ¥148 million due to low-profitability projects and increased depreciation burden from the new head office plant. Recognizing sales from the order backlog and improving profitability management remain challenges.
Last updated: July 17, 2026